FSM Wealth Advisors LLC Purchases New Holdings in CVS Health Corporation $CVS

Key Points

• FSM Wealth Advisors LLC has acquired a new stake in CVS Health Corporation, purchasing 9,914 shares valued at approximately $661,000.
• CVS Health has received multiple upgrades from analysts, with the current average rating of "Moderate Buy" and a consensus target price of $82.57.
• The company declared a quarterly dividend of $0.665 per share, with an annualized yield of 3.3%, set to be paid on November 3rd.

FSM Wealth Advisors LLC purchased a new stake in CVS Health Corporation (NYSE:CVS - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 9,914 shares of the pharmacy operator's stock, valued at approximately $661,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CVS. Harbor Asset Planning Inc. bought a new stake in CVS Health during the second quarter worth $30,000. Bell Investment Advisors Inc increased its holdings in shares of CVS Health by 119.8% during the first quarter. Bell Investment Advisors Inc now owns 455 shares of the pharmacy operator's stock worth $31,000 after buying an additional 248 shares in the last quarter. Roxbury Financial LLC increased its holdings in shares of CVS Health by 78.3% during the second quarter. Roxbury Financial LLC now owns 460 shares of the pharmacy operator's stock worth $32,000 after buying an additional 202 shares in the last quarter. ORG Partners LLC increased its holdings in shares of CVS Health by 418.9% during the second quarter. ORG Partners LLC now owns 467 shares of the pharmacy operator's stock worth $32,000 after buying an additional 377 shares in the last quarter. Finally, Saudi Central Bank acquired a new position in shares of CVS Health during the first quarter worth $34,000. 80.66% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of CVS Health from a "hold" rating to a "buy" rating in a report on Sunday, September 21st. Wolfe Research increased their price objective on CVS Health from $80.00 to $85.00 and gave the company an "outperform" rating in a report on Monday, September 22nd. Baird R W upgraded CVS Health from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Leerink Partners increased their price objective on CVS Health from $86.00 to $95.00 and gave the company an "outperform" rating in a report on Thursday, October 16th. Finally, Morgan Stanley raised their price target on shares of CVS Health from $82.00 to $89.00 and gave the company an "overweight" rating in a research report on Tuesday, October 14th. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $82.57.

CVS Health Trading Down 1.4%

NYSE:CVS opened at $80.86 on Thursday. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $102.56 billion, a PE ratio of 22.59, a price-to-earnings-growth ratio of 0.92 and a beta of 0.60. The firm's 50 day moving average is $75.02 and its 200 day moving average is $68.45. CVS Health Corporation has a 12 month low of $43.56 and a 12 month high of $83.52.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.46 by $0.35. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The business had revenue of $98.92 billion during the quarter, compared to analyst estimates of $94.87 billion. During the same period in the previous year, the business earned $1.83 EPS. CVS Health's revenue was up 8.4% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd will be given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date is Thursday, October 23rd. CVS Health's payout ratio is 74.30%.

Insider Activity at CVS Health

In other news, Director Anne A. Finucane sold 7,500 shares of the business's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total transaction of $532,650.00. Following the completion of the transaction, the director directly owned 22,156 shares in the company, valued at $1,573,519.12. The trade was a 25.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.22% of the stock is owned by company insiders.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.